IQVIA Expands Partnership with Veeva for Clinical Operations Enhancements

In a significant move within the healthcare technology landscape, IQVIA (NYSE: IQV) and Veeva Systems (NYSE: VEEV) have announced an expansion of their partnership, aiming to improve the efficiency of clinical operations. This collaboration centers around the adoption of Veeva's Clinical Trial Management System (CTMS), electronic Trial Master File (eTMF), Study Startup, and Site Connect as standardized applications for all of IQVIA's clinical development studies.

An Enhanced Collaboration

The expansion builds on an existing Electronic Data Capture (EDC) partnership that aims to streamline various clinical processes. By merging their expertise, IQVIA and Veeva intend to bolster clients' capabilities in managing clinical trials. According to Richard Staub, President of Research and Development Solutions at IQVIA, this partnership allows clinical teams to benefit from a more interconnected approach, thanks to the seamless integration of each company's technologies.

This initiative aims at not only increasing the speed and efficiency of clinical studies but also enhancing the alignment with study sites and enabling more informed decision-making. The ultimate goal of this collaboration is to expedite the delivery of transformative therapies to patients who need them the most.

Flexibility and Client-Centric Solutions

One of the standout features of this expanded partnership is the flexibility it offers clients. Organizations can still opt for their preferred EDC, Randomization and Trial Supply Management (RTSM), and electronic Clinical Outcome Assessment (eCOA) technologies, ensuring they meet their specific operational needs. Richard Staub highlighted the importance of allowing clients to choose the solutions that best suit their requirements, including access to IQVIA's innovative features.

Peter Gassner, Founder and CEO of Veeva, expressed enthusiasm about the enhanced collaboration. He noted that this partnership marks an exciting step forward in their joint efforts. Veeva's commitment to seamless product and service integration is pivotal in enhancing patient access to innovations.

The Future of Clinical Trial Management

The integration of IQVIA and Veeva's solutions promises to revolutionize clinical trial management. With Veeva's systems readily available through IQVIA for sponsors seeking to utilize the complete Veeva technology stack, the partnership aims to accommodate a variety of therapy developments, from pharmaceuticals to medical devices.

IQVIA itself is a global leader in clinical research services, market analysis, and health data for the life sciences. By employing their Connected Intelligence™ framework, IQVIA provides actionable insights based on high-quality health data and advanced analytics. The company is committed to leveraging artificial intelligence responsibly while meeting industry standards for privacy, compliance, and patient safety.

With more than 94,000 employees spread across over 100 countries, IQVIA strives to expedite the development and commercialization of innovative medical therapies, ultimately enhancing treatment outcomes for patients globally.

Protecting Patient Privacy

IQVIA prides itself on maintaining high standards for patient privacy. Utilizing various technologies and measures, the company ensures the protection of personal data while still generating and analyzing information vital for healthcare stakeholders. This approach allows a better understanding of disease patterns, enabling the linkage of precise treatments necessary for improved recovery outcomes.

For biotechnology, medical device, and pharmaceutical companies, IQVIA's insights and capabilities help further their understanding of diseases, human behaviors, and scientific advances essential for developing better therapies.

For more information about IQVIA, their services, and ongoing innovations, visit www.iqvia.com.

About Veeva Systems

Veeva operates as a cloud provider specialized for the life sciences industry, offering applications, data, and consulting services. With a commitment to innovation and product quality, Veeva serves more than 1500 customers, ranging from leading pharmaceutical companies to emerging biotech firms. The company's dedication to aligning stakeholder interests underscores its mission to foster success across the life sciences landscape.

Further details are available at veeva.com.

As this partnership continues to evolve, the healthcare industry may look forward to enhanced clinical trials that promise to accelerate access to groundbreaking therapies for patients worldwide.